Optum Rx to Adopt Flat‑Fee PBM Model for 61 Million Members by 2027

Why It Matters

The flat‑fee model promises greater price transparency for employers, health plans, and patients, potentially lowering out‑of‑pocket costs and simplifying budgeting for drug spend. By decoupling PBM revenue from manufacturer rebates, Optum Rx may set a new industry benchmark that forces competitors to rethink legacy rebate structures, accelerating a shift toward value‑based pharmacy benefits. For the broader healthcare system, the change could reduce administrative complexity, curb hidden fees, and improve medication adherence by giving patients clear cost information at the point of care. If other large PBMs follow suit, the cumulative effect could be a more competitive market that rewards efficiency and patient‑centered pricing rather than opaque rebate negotiations.

Key Takeaways

• Optum Rx will move all PBM customers to a flat‑fee, per‑member pricing model by Dec 31 2027.
• The change covers roughly 61 million members and over 67,000 community and home‑delivery pharmacies.
• 33 % of drug reauthorizations (11 % of all prior authorizations) have been eliminated for 270 chronic‑condition meds.
• 100 % of community and independent pharmacies in the network now operate under cost‑based payment terms.
• The shift aligns with the Consolidated Appropriations Act of 2026, which mandates rebate pass‑through and fair‑market‑value PBM compensation for Medicare Part D.

Pulse Analysis

Optum Rx’s decision to abandon rebate‑driven pricing is both a strategic response to regulatory pressure and a calculated bet on long‑term market leadership. By 2027, the flat‑fee model could give UnitedHealth a clear differentiator in a crowded PBM space where price opacity has eroded trust among employers and plan sponsors. The move also leverages Optum’s scale—its 61 million‑member base and extensive pharmacy network provide the bargaining power needed to negotiate favorable drug prices without relying on rebates.

Historically, PBMs have used spread pricing and manufacturer rebates to generate margins, often at the expense of plan sponsors and patients. The new federal rules aim to eliminate that misalignment, but they also threaten the profitability of firms that have built their business models around those mechanisms. Optum’s early adoption signals confidence that technology‑driven tools—like real‑time pricing displays and automated prior‑authorization reductions—can offset lost rebate revenue while delivering value to members.

Competitors such as CVS Health’s Caremark and Cigna’s Express Scripts will likely feel pressure to announce similar flat‑fee structures or risk losing contracts to a more transparent Optum offering. However, the transition will not be painless; PBMs must manage the shift in revenue streams, ensure pharmacies remain financially viable under cost‑based payments, and maintain service quality. The next few years will test whether flat‑fee PBMs can sustain margins while delivering the promised cost savings, and whether the industry as a whole can move toward a more transparent, patient‑centric pharmacy benefit ecosystem.